(BBIO) BridgeBio Pharma - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 13.319m USD | Total Return: 57.1% in 12m
Avg Turnover: 172M
Qual. Beats: -2
Rev. Trend: 84.9%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -5.4 is critical
Beneish M-Score -1.20 > -1.5 - likely earnings manipulation
Altman Z'' -12.08 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
BridgeBio Pharma, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and delivering treatments for patients with genetic diseases. The company operates in the biotechnology sub-sector of healthcare, targeting rare and monogenic conditions with high unmet medical need. Its commercial portfolio includes Attruby, an oral TTR stabilizer for transthyretin amyloid cardiomyopathy, and NULIBRY (Fosdenopterin) for molybdenum cofactor deficiency.
The companys pipeline spans multiple late-stage clinical programs, including low-dose infigratinib (Phase 3) for achondroplasia, Encaleret (Phase 3) for hypoparathyroidism-related disorders, BBP-418 (Phase 3) for LGMD2I, and BBP-812, an AAV-based gene therapy for Canavan disease. BridgeBio also pursues programs in oncology and gene therapy, supported by licensing and collaboration agreements with partners such as Bayer, Alexion, Stanford University, and Novartis. Founded in 2015 and headquartered in Palo Alto, California, the company went public in 2019 and is listed on NASDAQ under the ticker BBIO.
| Net Income: -725.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA 24.66 > 1.0 |
| NWC/Revenue: 62.42% < 20% (prev 426.2%; Δ -363.8% < -1%) |
| CFO/TA -0.32 > 3% & CFO -444.0m > Net Income -725.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (194.8m) vs 12m ago 2.44% < -2% |
| Gross Margin: 93.78% > 18% (prev 95.35%; Δ -1.57% > 0.5%) |
| Asset Turnover: 51.49% > 50% (prev 14.45%; Δ 37.04% > 0%) |
| Interest Coverage Ratio: -5.41 > 6 (EBIT TTM -617.7m / Interest Expense TTM 114.2m) |
| A: 0.26 (Total Current Assets 1.18b - Total Current Liabilities 816.4m) / Total Assets 1.37b |
| B: -2.91 (Retained Earnings -3.99b / Total Assets 1.37b) |
| C: -0.55 (EBIT TTM -617.7m / Avg Total Assets 1.13b) |
| D: -0.62 (Book Value of Equity -2.27b / Total Liabilities 3.64b) |
| Altman-Z'' = -12.08 = D |
| DSRI: 0.39 (Receivables 205.2m/115.3m, Revenue 580.0m/127.4m) |
| GMI: 1.02 (GM 95.35% / 93.78%) |
| AQI: 0.63 (AQ_t 0.12 / AQ_t-1 0.20) |
| SGI: 4.55 (Revenue 580.0m / 127.4m) |
| TATA: -0.21 (NI -725.9m - CFO -444.0m) / TA 1.37b) |
| Beneish M = -1.20 (Cap -4..+1) = D |
As of June 22, 2026, the stock is trading at USD 66.27 with a total of 3,815,604 shares traded.
Over the past week, the price has changed by -1.89%,
over one month by -5.71%,
over three months by -4.78% and
over the past year by +57.13%.
BridgeBio Pharma has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy BBIO.
- StrongBuy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 102.7 | 55% |
P/S = 22.9647
P/B = 123.6828
Revenue TTM = 580.0m USD
EBIT TTM = -617.7m USD
EBITDA TTM = -608.8m USD
Long Term Debt = 1.93b USD (from longTermDebt, last quarter)
Short Term Debt = 573.4m USD (from shortTermDebt, last quarter)
Debt = 3.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.7m
Net Debt = 2.46b USD (calculated: Debt 3.40b - CCE 940.2m)
Enterprise Value = 15.8b USD (13.3b + Debt 3.40b - CCE 940.2m)
Interest Coverage Ratio = -5.41 (Ebit TTM -617.7m / Interest Expense TTM 114.2m)
EV/FCF = -34.75x (Enterprise Value 15.8b / FCF TTM -454.1m)
FCF Yield = -2.88% (FCF TTM -454.1m / Enterprise Value 15.8b)
FCF Margin = -78.30% (FCF TTM -454.1m / Revenue TTM 580.0m)
Net Margin = -125.2% (Net Income TTM -725.9m / Revenue TTM 580.0m)
Gross Margin = 93.78% ((Revenue TTM 580.0m - Cost of Revenue TTM 36.1m) / Revenue TTM)
Gross Margin QoQ = 94.64% (prev 90.0%)
Tobins Q-Ratio = 11.51 (Enterprise Value 15.8b / Total Assets 1.37b)
Interest Expense / Debt = 3.36% (Interest Expense 114.2m / Debt 3.40b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -488.0m (EBIT -617.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.44 (Total Current Assets 1.18b / Total Current Liabilities 816.4m)
Debt / Equity = -1.50 (negative equity) (Debt 3.40b / totalStockholderEquity, last quarter -2.27b)
Debt / EBITDA = -4.05 (negative EBITDA) (Net Debt 2.46b / EBITDA -608.8m)
Debt / FCF = -5.42 (negative FCF - burning cash) (Net Debt 2.46b / FCF TTM -454.1m)
Total Stockholder Equity = -2.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -64.45% (Net Income -725.9m / Total Assets 1.37b)
RoE = 36.00% (negative equity) (Net Income TTM -725.9m / Total Stockholder Equity -2.02b)
RoCE = 682.4% (negative capital employed) (EBIT -617.7m / Capital Employed (Equity -2.02b + L.T.Debt 1.93b))
RoIC = -44.40% (negative operating profit) (NOPAT -488.0m / Invested Capital 1.10b)
WACC = 8.08% (E(13.3b)/V(16.7b) * Re(9.47%) + D(3.40b)/V(16.7b) * Rd(3.36%) * (1-Tc(0.21)))
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 5.02%
[DCF] Fair Price = unknown (Cash Flow -454.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.88 | # QB: -2
Revenue Correlation: 84.86 | Revenue CAGR: 371.7% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.59 | Chg30d=+3.49% | Revisions=-43% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.48 | Chg30d=+2.98% | Revisions=+14% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.22 | Chg30d=-8.45% | Revisions=+25% | GrowthEPS=+41.4% | GrowthRev=+92.2%
EPS next Year (2027-12-31): EPS=0.50 | Chg30d=+82.02% | Revisions=+14% | GrowthEPS=+122.3% | GrowthRev=+68.3%
[Analyst] Revisions Ratio: -43%